Posted by Michael Wonder on 16 May 2022
Korea clears permit for Samsung Bioepis’ Lucentis biosimilar after US
16 May 2022 - Samsung Bioepis received marketing approval for Amelivu (ranibizumab), a biosimilar referencing Lucentis to treat various eye diseases in Korea.
However, the local market release of the treatment will take some time due to a patent-related agreement between Samsung Bioepis and Genentech, the developer of the original drug, Lucentis.
